<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01244139</url>
  </required_header>
  <id_info>
    <org_study_id>215MS101</org_study_id>
    <nct_id>NCT01244139</nct_id>
  </id_info>
  <brief_title>Safety Study of BIIB033 in Subjects With Multiple Sclerosis</brief_title>
  <official_title>A Randomized, Blinded, Placebo-Controlled, Serial-Cohort, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic&#xD;
      profile of two intravenous infusions of BIIB033 administered two weeks apart in subjects with&#xD;
      MS.&#xD;
&#xD;
      Approximately 42 MS subjects are planned to be enrolled in the study in 7 separate groups&#xD;
      (i.e., 6 subjects per group). Each subsequent group will be administered a higher dose of&#xD;
      BIIB033. Before a higher dose group is allowed to start, a Drug Safety Review Committee will&#xD;
      review all safety data from previous groups enrolled, as well as data from another study&#xD;
      where BIIB033 is being administered to healthy volunteers (215HV101).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BIIB033 is a protein that acts on certain types of brain cells by blocking the function of&#xD;
      another protein called LINGO-1. It is believed that LINGO-1 is one of the reasons why nerves&#xD;
      in the brain of patients with MS do not repair well. It is thought BIIB033 may improve MS by&#xD;
      repairing damaged nerve tissue. LINGO-1 is also present in the brain of healthy people.&#xD;
&#xD;
      Subjects will take part in the 215MS101 study for up to 28 weeks. This includes a 4-week&#xD;
      screening period, a 2 week treatment period in which 2 doses of BIIB033 are given, and a&#xD;
      post-dosing safety follow up period of up to 22 weeks (depending on dose cohort).&#xD;
&#xD;
      The study tests vary at each of the individual visits and may include:&#xD;
&#xD;
      medical history evaluation, height and weight assessment, physical examination, neurological&#xD;
      examination, vital signs assessment (pulse, respiratory rate, blood pressure, and&#xD;
      temperature), MS performance score, electrocardiogram, cardiac monitoring, routine blood and&#xD;
      urine tests, drug concentration testing of the blood, hepatitis and HIV tests, blood clotting&#xD;
      tests, brain MRI scan, lumbar puncture, and drugs of abuse screen and pregnancy test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate safety and tolerability profile of two IV infusions of BIIB033 in subjects with MS</measure>
    <time_frame>For duration of study / 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify incidence and types of adverse events</measure>
    <time_frame>For duration of study / 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of serious adverse events</measure>
    <time_frame>For duration of study / 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in clinical lab assessments and vital signs</measure>
    <time_frame>For duration of study / 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes form baseline in other safety measures: physical and neurological examinations, brain MRIs, and ECGs</measure>
    <time_frame>For duration of study / 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the repeat-dose serum PK profile of BIIB033</measure>
    <time_frame>For duration of study / 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the repeat-dose immunogenicity of BIIB033</measure>
    <time_frame>For duration of study / 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure the concentration of BIIB033 in the cerebrospinal fluid</measure>
    <time_frame>At specified timepoints in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore potential biomarkers of BIIB033 activity in the periphery and in the central nervous system</measure>
    <time_frame>At specified timepoints in the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Relapsing-Remitting Multiple Sclerosis</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Active study drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dummy drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB033</intervention_name>
    <description>IV infusion of 0.3, 1, 3, 10, 30, 60 or 100 mg/kg</description>
    <arm_group_label>Active study drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV infusion dummy drug</description>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Give informed consnet&#xD;
&#xD;
          -  Aged 18 to 60 years&#xD;
&#xD;
          -  Have relapsing remitting MS or secondary progressive MS&#xD;
&#xD;
          -  EDSS score of 1 to 6 inclusive&#xD;
&#xD;
          -  Body mass index of 18 to 30 kg/m2&#xD;
&#xD;
          -  Commitment to use effective contraception 6 months after last dose of study drug&#xD;
             Treatment with any interferon beta or glatiramer acetate is allowed to continue during&#xD;
             the study as long as the initiation of treatment was at least 3 months and the dose is&#xD;
             stable.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Primary progressive MS&#xD;
&#xD;
          -  Any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic,&#xD;
             urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, allergic or&#xD;
             anaphylactic reactions or other major disease&#xD;
&#xD;
          -  Clinically significant lab value at screening outside of normal range&#xD;
&#xD;
          -  Clinically significant ECG abnormality&#xD;
&#xD;
          -  Contraindication to MRI scans or lumbar punctures&#xD;
&#xD;
          -  Plans to undergo elective surgery during study&#xD;
&#xD;
          -  An MS relapse that has not resolved within 30 days before screening&#xD;
&#xD;
          -  History or postive test result for Hepatitis B, C and HIV&#xD;
&#xD;
          -  Serious infections within 3 months prior to Day -1&#xD;
&#xD;
          -  Treatment with MS medication within 12 months prior to Day -1: natalizumab,&#xD;
             daclizumab, azathioprine, methotrexate, iV immunoglobulin, plasmapheresis or&#xD;
             mycophenolate motefil&#xD;
&#xD;
          -  Prior treatment with total lymphoid irradiation, T cell or T-cell receptor&#xD;
             vaccination, alemtuzumab, mitoxantone, cyclophosphamide, rituximab, fingolimod.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tran JQ, Rana J, Barkhof F, Melamed I, Gevorkyan H, Wattjes MP, de Jong R, Brosofsky K, Ray S, Xu L, Zhao J, Parr E, Cadavid D. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm. 2014 Aug 21;1(2):e18. doi: 10.1212/NXI.0000000000000018. eCollection 2014 Aug.</citation>
    <PMID>25340070</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>November 18, 2010</study_first_submitted>
  <study_first_submitted_qc>November 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2010</study_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BIIB033</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>anti-LINGO-1 antibody</keyword>
  <keyword>Relapsing Remitting MS</keyword>
  <keyword>remyelination</keyword>
  <keyword>myelin repair</keyword>
  <keyword>Multiple ascending dose</keyword>
  <keyword>Secondary progessive MS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

